Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: AJAG who wrote (3323)	6/21/1999 4:22:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Does BancBoston Now Charge, In the face of a JNJ retreat from a superior weapon? Is this a trend we have yet to anticipate, when studies prove racemic version can do harm, then the owner pulls racemic from a weak market, for legal liability reasons? Lawyers, is the liability greater if the second isomer has been proven to be the cause of any harm? "By Stephanie O'Brien, CBS MarketWatch Last Update: 5:50 PM ET Jun 10, 1999 NewsWatch NEW YORK (CBS.MW) -- BancBoston Robertson Stephens on Thursday cut earnings estimates for specialty-pharmaceuticals maker Sepracor, due to recent partnerships and clinical data. "We are lowering our earnings estimates on Sepracor (SEPR: news, msgs) to reflect changes primarily due to Johnson & Johnson's (JNJ: news, msgs) decision not to co-promote the (antihistamine) Norastemizole," said Donald Ellis, an analyst at the investment firm, in a note to clients. Ellis didn't elaborate on the clinical data in the after-the-bell press release."